Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

Similar documents
Out-Patient Billing CPT Codes

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

The Center for PERSONALIZED DIAGNOSTICS

Liquid biopsy: the experience of real life case studies

August 17, Dear Valued Client:

Molecular Testing in Lung Cancer

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

PRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Genomic Medicine: What every pathologist needs to know

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

MET skipping mutation, EGFR

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Transform genomic data into real-life results

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Accel-Amplicon Panels

Clinical Grade Genomic Profiling: The Time Has Come

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

EXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR)

EBUS-TBNA Diagnosis and Staging of Lung Cancer

NeoTYPE Cancer Profiles

QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing

NeoTYPE Cancer Profiles

Corporate Medical Policy

Enabling Personalized

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Personalized Genetics

The Pathology of Neoplasia Part II

HSL-Advanced Diagnostics 2018 / 19 Test & Service List

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges

Disclosures Genomic testing in lung cancer

Oncomine Focus assay panel and Oncomine Knowledgebase Reporter.

EXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)

Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges

Next generation histopathological diagnosis for precision medicine in solid cancers

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

MEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia

Diagnostica Molecolare!

Lukas Bubendorf Pathologie. Liquid biopsies

Illumina s Cancer Research Portfolio and Dedicated Workflows

IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

Next generation diagnostics Bringing high-throughput sequencing into clinical application

Date of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17

Diagnostic application of SNParrays to brain cancers

Secuenciación masiva: papel en la toma de decisiones

Molecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA

Prior Authorization. Additional Information:

Enterprise Interest Thermo Fisher Scientific / Employee

Detecting Oncogenic Mutations in Whole Blood

Precision Medicine Knowledgebase (PMKB)

Product Overview CELL-FREE DNA BCT CELL-FREE RNA BCT CELL-FREE DNA URINE PRESERVE CYTO-CHEX BCT STRECK CELL PRESERVATIVE

Comprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory

patients in the era of

Development of Circulating Tumor DNA

Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each

Clinical, Pathologic and Molecular Updates

molecular oncology services

Best of ASCO 2014 Sarcoma

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Cell-free tumor DNA for cancer monitoring

Liquid biopsy in lung cancer: The EGFR paradigm

RNA Extraction from Formalin Fixed Paraffin Embedded (FFPE) Tissue Enabling Next Generation Detection of Gene Fusions

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff

The NCI- MATCH (EAY131) Precision Medicine Trial: Lessons Learned and Status Update

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018

Comparative Effectiveness Research (CER) and Personalized Medicine: Policy, Science, and Business

October Billing and compliance. Coagulation. Immunohistochemistry. Immunology. Referral testing ICD 10

UCL-Advanced Diagnostics. 2015/16 Service Update

Integration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support

Diagnostic test Suggested website label Description Hospitals available

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

Regulatory Landscape for Precision Medicine

Personalized Medicine: Lung Biopsy and Tumor

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

Click to edit Master /tle style

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

Molecular Oncology, oncology parameters see each test

Transcription:

Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr: Sent in: Paraffin block Frozen tissue EDTA-Blood Cyto. Smear Plasma DNA Patient male female Surname: Name: Date of birth: Address: Diagnosis: Specific questions: Invoice to: Client Patient other: Date: Signature: Sender (if not client): Report copy to: General Informed Consent from USZ filled out and attached: Select analysis on the next pages Sample request and sending address see last page 7FO-Einsendeformular_SP_englisch_2-1310-70024-PTK.docx 16.02.2018 Seite 1 von 5

Lung EGFR KRAS (incl. EGFR, KRAS, ALK Mutations; ALK, ROS1, RET Translocations, MET Exon 14 skipping, MET und ERBB2 Amplifications) Lung cfdna Assay (incl. EGFR, KRAS) ALK ROS1 PD-L1 c-met HER2 GI-Tract KRAS (incl. KRAS, BRAF, NRAS, KIT, PDGFRA Mutations; PDGFRA, KIT Amplifications) (incl. KRAS, BRAF, NRAS) MSH2, MSH6, PMS, MLH1 BRAF VE1 (IHC, p.v600e spezifisch) Skin (incl. BRAF, NRAS, KIT, GNAQ, GNA11 Mutations) (incl. BRAF, NRAS) BRAF VE1 (IHC, p.v600e spezifisch) Brain (incl. AKT1, BRAF, IDH1, IDH2, EGFR variant III Mutations, KIAA1549:BRAF Fusions) (incl. AKT1, BRAF) 7FO-Einsendeformular_SP_englisch_2-1310-70024-PTK.docx 16.02.2018 Seite 2 von 5

Soft tissue / Bone (incl. CTNNB1 Mutations) Archer Sarcoma (incl. t(11;22), t(x;18), t(12;16), t(12;22), t(21;22), t(7;16), t(11;16), t(1;13), t(2;13)) (incl. CTNNB1, GNAS) Ovary / Breast / Prostate / Pancreas Oncomine BRCA (incl. all coding exons; BRCA1+2 Deletions; LargeINDELS, Duplications) (incl. ERBB2 Mutations and Amplifications) Breast cfdna Assay (incl. ERBB2) HER2 Progesteronrezeptor Östrogenrezeptor Hematopathology TP53 (incl. all coding exons) TrueSight Myeloid (incl. BRAF, MYD88) (incl. BRAF, MAP2K1) (incl. BRAF, MAP2K1) 7FO-Einsendeformular_SP_englisch_2-1310-70024-PTK.docx 16.02.2018 Seite 3 von 5

Single / sequential mutation analyses Order form Diagnostische Molekularpathologie Tel.: (+41) 044 255 39 45 FISH-Analyses Order form ISH; Labor für In situ-techniken Tel.: (+41) 044 255 19 87 Prognostic Order form Laboratory of Molecular Tel.: (+41) 43 253 0334 7FO-Einsendeformular_SP_englisch_2-1310-70024-PTK.docx 16.02.2018 Seite 4 von 5

Probe requests for the different analyses and price Please send material for analyses together with the order form to: UniversitätsSpital Zürich Institut für Pathologie und Molekularpathologie Histologielabor PATH F 1 z.hd. Diagnostische Tumor-Genomanalyse Schmelzbergstrasse 12 8091 Zürich / Schweiz Analysis from fixed tissue possible; if possible add an actual HE staining (TARMED-Pos. 1x 37.0540: 470.6 TP) KRAS (TARMED-Pos. 1x 37.0540: 470.6 TP) EGFR (TARMED-Pos. 1x 37.0540: 470.6 TP) Analysis from fixed and frozen tissue, cytological smears and DNA/RNA possible Oncomine TM BRCA Research Assay (TARMED-Pos. 4x 37.0540: 1 882.40 TP) (DNA, RNA) (TARMED-Pos. 5x 37.0540: 2'353 TP) Analysis from fixed and frozen tissue, DNA and EDTA-Blood possible Ion AmpliSeq TP53 (TARMED-Pos. 2x 37.0540: 941.20 TP) Analysis from fixed, frozen tissue and RNA possible Archer Sarcoma (TARMED-Pos. 3x 37.0540: 1'410.60 TP) Analysis from EDTA-Blood, EDTA-bone marrow aspirate or biopsy in NaCl and DNA possible TruSight Myeloid Sequencing (TARMED-Pos. 3x 37.0540: 1'410.60 TP) Bone marrow biopsy / punch in NaCl, Monday Thursday, at latest 17:30 Bone marrow aspirat or blood, Monday Thursday, at latest 17:30, Friday at latest 14:00 Analysis from EDTA-Blood and plasma possible (): Lung cfdna Assay (DNA) (TARMED-Pos. 5x 37.0540: 2'353 TP) (DNA) (TARMED-Pos. 5x 37.0540: 2'353 TP) Breast cfdna Assay (DNA) (TARMED-Pos. 5x 37.0540: 2'353 TP) Send 10-20 ml blood in a K2-EDTA Plasma tube within 12 h at room temperature to the USZ (at latest 16:00). Please provide date and time from blood taking. If the sample cannot be sent within 12 h, please use following tube: Cell-Free DNA BCT (Streck; Katalog-Nr.: 218961) and send it to the address depicted above at room temperature. Please provide date and time from blood taking. If you do not have such tubes, we may send you one. 7FO-Einsendeformular_SP_englisch_2-1310-70024-PTK.docx 16.02.2018 Seite 5 von 5

2024 © healthdocbox.com Privacy Policy | Terms of Service | Feedback